Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Rhea-AI Summary

Daxor (Nasdaq: DXR) has announced the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. The company is partnering with a leading 1,000+ bed comprehensive medical center in western Florida to provide lab processing of patient tests, offering a rapid 24-hour testing service. This implementation aims to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associated costs.

The BVA-100™ Blood Volume Diagnostic facilitates optimal diagnosis of patient volume status, which is important for both in-patient and out-patient heart failure care. Daxor's CEO, Michael Feldschuh, emphasized that their BVA diagnostic delivers 98% accurate, actionable data to guide individualized fluid management, enhancing patient outcomes and optimizing costs. The ezBVA Lab service is reimbursed by both public and private insurance in inpatient and outpatient care using established CPT codes.

Positive

• Partnership with a leading 1,000+ bed comprehensive medical center in Florida
• Expansion of blood volume analysis capabilities through ezBVA Lab service
• BVA-100™ diagnostic delivers 98% accurate, actionable data for heart failure care
• ezBVA Lab service reimbursed by both public and private insurance

Negative

• None.

Medical Research Analyst

The implementation of Daxor's BVA-100™ Blood Volume Diagnostic at a major Central Florida hospital marks a significant advancement in heart failure patient care. This 98% accurate diagnostic tool addresses a critical aspect of heart failure management - volume status. By providing precise data on blood volume, it enables personalized fluid management, which is important for optimizing treatment outcomes.

The ezBVA Lab service offers a cost-effective solution for hospitals to access this technology without significant capital investment. With both public and private insurance coverage for inpatient and outpatient care, this service could potentially improve accessibility to advanced diagnostics across various healthcare settings. The 24-hour turnaround time for test results also suggests improved efficiency in patient care workflows.

Financial Analyst

Daxor's expansion through the ezBVA Lab service represents a strategic move to increase market penetration. By partnering with a 1,000+ bed comprehensive medical center, Daxor gains access to a large patient population, potentially driving significant revenue growth. The service model eliminates the need for hospitals to make upfront capital investments, which could accelerate adoption rates.

The established CPT codes for reimbursement from both public and private insurers provide a stable revenue stream. This business model combines the benefits of recurring revenue with reduced customer acquisition costs, as hospitals can easily implement the service. However, investors should monitor the scalability of this service model and its impact on Daxor's profit margins compared to direct equipment sales.

Healthcare Management Consultant

The adoption of Daxor's BVA technology by a leading Florida hospital signifies a growing trend towards precision medicine in cardiac care. This move aligns with the healthcare industry's focus on value-based care, aiming to improve patient outcomes while reducing costs. The BVA diagnostic's ability to enhance the effectiveness of existing therapies could lead to shorter hospital stays and reduced readmission rates, key metrics in healthcare performance.

The ezBVA Lab service model is particularly attractive in the current healthcare environment, where capital expenditures are scrutinized. It allows hospitals to improve care quality without significant upfront costs. This could accelerate the adoption of advanced diagnostics in both large and small healthcare facilities, potentially reshaping the standard of care for heart failure patients across diverse healthcare settings.

1,000 Bed Comprehensive Medical Center Launches ezBVA Lab Program

Oak Ridge, TN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. Daxor will partner with the hospital to provide lab processing of its patient tests, providing a rapid 24-hour testing service that is highly efficient for the hospital to implement.

The hospital is a leading 1,000+ bed comprehensive medical center in western Florida aiming to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associated costs. BVA facilitates optimal diagnosis of patient volume status, which is a cornerstone of both in-patient and out-patient heart failure care, enabling existing therapies to be far more effective for treating patients and reducing associated costs.

“Volume management is crucial in heart failure care,” said Michael Feldschuh, Daxor’s CEO and President. “Our BVA diagnostic delivers 98% accurate, actionable data to guide individualized fluid management to enhance patient outcomes and optimize costs. For facilities seeking BVA access without capital investment, our ezBVA Lab service is a reliable option for processing BVA samples. The service is reimbursed by both public and private insurance in both inpatient and outpatient care using established CPT codes.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What is Daxor's new partnership for its BVA-100™ Blood Volume Diagnostic?

Daxor (DXR) has partnered with a leading 1,000+ bed comprehensive medical center in western Florida to implement its BVA-100™ Blood Volume Diagnostic for heart failure patient care through its ezBVA Lab service.

How does Daxor's BVA-100™ diagnostic benefit heart failure treatment?

Daxor's BVA-100™ diagnostic provides 98% accurate, actionable data to guide individualized fluid management in heart failure patients, optimizing treatment outcomes, improving patient experiences, and reducing associated costs.

What is the ezBVA Lab service offered by Daxor (DXR)?

The ezBVA Lab service is Daxor's offering that provides lab processing of patient tests with a rapid 24-hour turnaround, allowing hospitals to implement blood volume analysis without capital investment.

Is Daxor's ezBVA Lab service covered by insurance?

Yes, Daxor's ezBVA Lab service is reimbursed by both public and private insurance for inpatient and outpatient care using established CPT codes.